Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia
Quince Therapeutics, Inc. (QNCX)
Company Research
Source: Business Wire
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that the last patient has completed their last visit in the company’s pivotal Phase 3 NEAT (Neurological Effects of eDSP in Subjects with A-T; NCT06193200/IEDAT-04-2022) clinical trial of its lead asset, encapsulated dexamethasone sodium phosphate (eDSP), in patients with Ataxia-Telangiectasia (A-T). The company expects to report topline results from this study in the middle of the first quarter of 2026.Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, said, “Completing our pivotal Phase 3 NEAT clinical trial marks a major milestone for Quince as we rapidly move toward reporting topline results in the middle of the first quarter of 2026. Conducted under a Special Protocol Assessment agreement with the U.S. Food and Drug Adm
Show less
Read more
Impact Snapshot
Event Time:
QNCX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
QNCX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
QNCX alerts
High impacting Quince Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
QNCX
News
- Quince Therapeutics (NASDAQ:QNCX) had its price target raised by analysts at D. Boral Capital from $4.00 to $5.00. They now have a "buy" rating on the stock.MarketBeat
- Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders [Yahoo! Finance]Yahoo! Finance
- Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel DisordersBusiness Wire
- Quince Therapeutics to Participate at Investor Events in December 2025Business Wire
- Quince Therapeutics (NASDAQ:QNCX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $4.00 price target on the stock.MarketBeat
QNCX
Earnings
- 11/12/25 - Miss
QNCX
Sec Filings
- 12/12/25 - Form 4
- 12/8/25 - Form 4
- 11/14/25 - Form SCHEDULE
- QNCX's page on the SEC website